Navigation Links
Remicade Therapy Effective in Treating Severe Psoriasis

imab for Psoriasis in a [REMICADE] Efficacy and Safety Study (EXPRESS II), among patients with severe psoriasis who were either dissatisfied with or were intolerant to phototherapy, 73 percent of those treated with REMICADE achieved PASI 75 at week 10, compared with two percent of patients receiving placebo (P < 0.001). Sixty-nine percent of patients who were dissatisfied with or were intolerant to one or more systemic therapies prior to starting REMICADE achieved PASI 75 at week 10, compared with zero patients in the placebo group (P < 0.001).

A separate analysis from the European Infliximab for Psoriasis [REMICADE] Efficacy and Safety Study (EXPRESS) trial showed that among study patients with psoriasis affecting the nails at baseline who were treated with REMICADE 5 mg/kg, seven percent, 26 percent and 45 percent had clearance of nail psoriasis at weeks 10, 24 and 50, respectively, compared with 5 percent of patients in the placebo group at week 24 (P = 0.0002). In addition, at weeks 10 and 24, the mean percent improvements in the Nail Psoriasis Severity Index (NAPSI) scores were 27 percent and 57 percent, respectively, among patients in the REMICADE 5 mg/kg group compared with disease worsening observed among patients receiving placebo with increases in NAPSI scores of eight percent and four percent, respectively (P < 0.001, for both).

"These data are promising because the results demonstrate the efficacy of REMICADE in psoriasis patients whose disease is affecting the nails, a difficult-to-treat and chronic manifestation that can affect a large proportion of patients with psoriasis," said Phoebe Rich, MD, associate professor of dermatology, Oregon Health Sciences University. "Symptoms associated with nail disease may include deep holes in the nails or separation of the nails from the nail beds, which often result in pain and discomfort and may affect an individual's ability to perform daily activities. Given the nature of these symptoms,
'"/>




Page: 1 2 3

Related medicine news :

1. Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder
2. Cancer Doctors Okays Controversial Prostate Therapy
3. Consensus on "Combination Therapy" for Breast Cancer
4. Gene Therapy shows promise in treating Hemophilia
5. "Make AIDS Therapy affordable" - Physicians demand
6. Hormone replacement Therapy a headache
7. Simple Therapy
8. Therapy for stopping the spread of cancer cells
9. Gene Therapy Destroys Pancreatic Cancer Cells
10. Letrozole Beats Tamoxifen in Breast Cancer Therapy
11. Garlic Supplements Impede HIV Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Remicade Therapy Effective Treating Severe Psoriasis

(Date:11/21/2014)... 20, 2014 (HealthDay News) -- Certain genes might prevent ... to a fifth of people with type 2 diabetes, ... been pondered by doctors working with diabetic patients, one ... under the impression that exercise helps decrease insulin resistance ... Pena, director of the Center for Weight Management at ...
(Date:11/21/2014)... Richard Wolfe, co-founder and CEO of ... benefits administration strategies during the Game Changer session ... This Game Changer breakout session enables emerging providers ... solutions and best practices to top HR leaders. ... exchange between health and welfare benefits partners, HR ...
(Date:11/21/2014)... 2014 Center for Autism and Related ... Insurance Funding for Autism Workshops” to help parents of ... through the insurance coverage process. Parents will learn ... the most effective ways to access coverage. The first ... 6-8:00 p.m. at 331 Montvale Ave., 5th Floor in ...
(Date:11/21/2014)... The Ohio Children’s Trust Fund has agreed to ... of Pediatrics (Ohio AAP, [http://www.ohioaap.org ) to raise ... caregivers throughout Ohio. The new contract, which began November ... to continue the campaign that originally started in 2013. ... to continue partnering with the Ohio AAP to provide ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 The typical ... high calorie dishes, plenty of gravy and a myriad ... be the best time of year to begin losing ... Doc has uncovered the secret to losing unhealthy, embarrassing ... fattening holiday recipes. , The insight to Diet Doc’s ...
Breaking Medicine News(10 mins):Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 3Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 2Health News:Ohio AAP and Ohio Children’s Trust Fund Continue Partnership for Safe Sleep Education Campaign 3Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 2Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 3Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 4
... , BOTHELL, Wash., Sept. 18 ... today that on September 15, 2009, the NYSE Amex LLC ... to its previously disclosed listing deficiency as set forth in ... relates to the Company,s failure to maintain stockholder,s equity of ...
... , , , ... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of ... 57, has embarked on his third annual "Grandpa,s Road Trip" with ... the NxStage System One provides Mr. Wells the opportunity to fit ...
... , , , , ... hip abnormalities, combined with advances in diagnostic imaging techniques and minimally ... chronic, misdiagnosed hip pain. , , Increasingly, ... of degenerative hip disease, get patients back to their chosen activities ...
... , Statement of Andy Stern, President ... Andy Stern, President of the Service Employees International ... wing extremists to silence working families by attacking progressive individuals and ... moment of profound change for this country -- from kitchen tables ...
... Calif., Sept. 18 Solta Medical, Inc. (Nasdaq: SLTM ... that it will present at the Maxim Group Growth Conference to ... New York Hotel in New York, NY. The Company,s presentation ... Stephen J. Fanning, Chairman, President and Chief Executive Officer, will ...
... CHICAGO, Sept. 18 As economic, social and political ... state,s leading provider of addiction treatment services is expanding its ... afford expensive clinics but also fail to qualify for government-funded ... a 41-year-old non-profit organization, serves more than 29,000 patients in ...
Cached Medicine News:Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 2Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 4Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 5Health News:Working Women and Men Will Not Be Silenced by Right Wing Attack Dogs; SEIU Members and Other Working Americans Will Continue to Speak Out For the America We Believe In 2Health News:Solta Medical to Present at the Maxim Group Growth Conference 2Health News:Gateway Responding To Increased Need for Treatment Among Middle-Income Substance Abusers 2
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... MELVILLE, N.Y. , Nov. 21, 2014 /PRNewswire/ ... of the world,s largest health care services companies, and ... world,s largest provider of health care products and services ... announced that the companies have entered into a long-term ... service and product offerings to office-based medical practices.  This ...
(Date:11/21/2014)... research firm Kalorama information says that 2014 will be ... medical device industry.  The firm thinks the $360 billion-dollar ... growth this year, which led firms to look to ... entrance by acquisition into new competitive zones.  The company ... Global Market for Medical Devices, 5 th Edition ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... The Intellectual Property portfolio of TIGR® Matrix ... the granting of a second U.S. patent related to ... was developed based on the hypothesis that soft tissue ... mechanical load – a process known as ,mechanotransduction, which ...
... PRGO;TASE) today announced that it has received final approval ... abbreviated new drug application (ANDA) for Desloratadine tablets (5 ... upon its filing of an ANDA containing a Paragraph ... the terms of the settlement, Perrigo can commercially launch ...
Cached Medicine Technology:Novus Scientific Announces a New U.S. Patent for a Mesh Implant Comprising Two Different Resorbable Materials with Different Degradation Times and Specific Mechanical Behaviours; U.S. Patent No. -- 8,083,755 2Perrigo Announces FDA Final Approval for Desloratadine 2
The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
... catheter is specifically designed for use with ... EP deflectable NAVI-STAR catheter houses a Biosense ... indicate, in real time, exact location points ... local electrogram information. The NAVI-STAR electro-anatomical navigation ...
For Atrial Mapping. Biosense Webster offers a complete line of specialty 20-pole catheters. The CRISTA CATH 20-pole deflectable catheter is designed for positioning along the crista terminals....
... Steerable Catheter. Steerable atrial mapping ... designs and a unique 45 ... to 24 electrodes, regular and ... active tip electrodes, and bipolar ...
Medicine Products: